$23.01
-0.18-0.78%
Últ. Act.: Oct 20, 4:28 AM
$23.35
0.160.69%
Collegium Pharmaceutical (COLL) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Collegium Pharmaceutical (COLL) publicó su última previsión de agosto 6, 2026 para fiscal year 2026. La compañía estimó ingresos en un rango de $825M - $855M para el período.
En comparación con la previsión anterior, Collegium Pharmaceutical reducido redujo su previsión de ingresos desde un rango anterior de $865M - $895M.
Collegium Pharmaceutical ha emitido 23 actualizaciones de orientación entre el noviembre 3, 2022 y el agosto 6, 2026. During this period, the company raised its outlook 8 times and lowered it 2 times, providing investors with insight into management's evolving expectations.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $1.70 | $1.46 | $2.09 | $1.79 |
| Actual | $1.92 | $1.76 | $2.04 | $2.25 |
| Surprise | +12.9% | +20.5% | -2.39% | +25.7% |
| Revenue | ||||
| Estimate | $202.3M | $183.7M | $207.3M | $189.4M |
| Actual | $199.9M | $193.5M | $205.4M | $209.4M |
| Surprise | -1.19% | +5.32% | -0.88% | +10.6% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $1.79 | $1.92 | $1.07 | $1.22 |
| Revenue | ||||
| Consensus | $215.8M | $223.6M | — | — |
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $1.92 | $1.70 | 12.9 % |
| Q1 | May 7, 2026 | $1.76 | $1.46 | 20.5 % |
| Q4 | Feb 26, 2026 | $2.04 | $2.09 | -2.39 % |
| Q3 | Nov 6, 2025 | $2.25 | $1.79 | 25.7 % |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $199.88M | $202.28M | -1.19 % |
| Q1 | May 7, 2026 | $193.52M | $183.74M | 5.32 % |
| Q4 | Feb 26, 2026 | $205.45M | $207.28M | -0.88 % |
| Q3 | Nov 6, 2025 | $209.36M | $189.36M | 10.6 % |